GLI1 and neoplasm: In this study, the treatment with LDE225, the SMO inhibitor, showed an inefficient suppression of LMS tumor growth, concomitantly with no changes in SMO and Ki67 protein expression, as well as in gene expression of SMO, GLI1, and GLI2.